Leptomeningeal Carcinomatosis From Carcinoma of Unknown Primary in a Young Patient: A Case Report and a Literature Review.
carcinoma of unknown primary
caudal type homeobox 2
cytokeratin
leptomeningeal carcinomatosis
leptomeningeal metastasis
ovarian mucinous carcinoma
placental alkaline phosphatase
Journal
Journal of investigative medicine high impact case reports
ISSN: 2324-7096
Titre abrégé: J Investig Med High Impact Case Rep
Pays: United States
ID NLM: 101624758
Informations de publication
Date de publication:
Historique:
entrez:
20
8
2019
pubmed:
20
8
2019
medline:
9
4
2020
Statut:
ppublish
Résumé
Leptomeningeal carcinomatosis, leptomeningeal meningitis, or, as referred here, leptomeningeal metastasis (LM), is a rare but frequently fatal complication seen in advanced stage of cancer either locally advanced or after a metastasis of a known primary cancer. We present a rare and uncommon case of leptomeningeal metastases from carcinoma of unknown primary. A 32-year-old female was diagnosed with LM; however, no known primary carcinoma was identified after 2 separate biopsies. The first biopsy of the right pre-tracheal lymph node showed poorly differentiated pan-keratin (AE1 and AE3) and placental alkaline phosphatase with the possibility of germ cell origin. Second cytology of cervical lymphadenopathy was remarkable for cytokeratin 7 and 20, placental alkaline phosphatase, and CDX2 suggestive of germ line tumor with both mucinous ovarian and gastrointestinal carcinomas. Unfortunately, the LM progressed rapidly despite multiple cycles of germ cell origin directed systemic and intrathecal chemotherapy, and the patient opted for hospice care without getting a chance to identify the primary source.
Identifiants
pubmed: 31423841
doi: 10.1177/2324709619869380
pmc: PMC6699001
doi:
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2324709619869380Références
Mod Pathol. 2009 Oct;22(10):1321-7
pubmed: 19668151
J Clin Oncol. 1999 Oct;17(10):3110-6
pubmed: 10506606
J Investig Med High Impact Case Rep. 2013 Jun 18;1(2):2324709613494830
pubmed: 26425578
CNS Oncol. 2017 Oct;6(4):261-267
pubmed: 29057672
Neuro Oncol. 2011 Dec;13(12):1364-9
pubmed: 21865399
J Natl Compr Canc Netw. 2015 Oct;13(10):1191-202
pubmed: 26483059
Br J Cancer. 2001 Jan;84(2):157-63
pubmed: 11161370
Leuk Lymphoma. 2002 Mar;43(3):587-93
pubmed: 12002763
Case Rep Oncol. 2009 Oct 10;2(3):177-183
pubmed: 20737034
Mod Pathol. 1998 Aug;11(8):728-34
pubmed: 9720500
J Neurooncol. 2006 Jul;78(3):255-60
pubmed: 16344918
Cancer. 1976 Oct;38(4):1471-5
pubmed: 825215
Cancer. 2006 May 1;106(9):2021-7
pubmed: 16583432
Clin Cancer Res. 1999 Nov;5(11):3394-402
pubmed: 10589750
Neuro Oncol. 2008 Apr;10(2):208-15
pubmed: 18316473
Arch Pathol Lab Med. 2010 Feb;134(2):207-15
pubmed: 20121608
J Clin Oncol. 1993 Mar;11(3):561-9
pubmed: 8445432
J Neurooncol. 2009 Feb;91(3):271-7
pubmed: 18820836
Br Med J. 1971 Aug 26;3(5773):508-12
pubmed: 5109411
Breast Cancer Res Treat. 2013 May;139(1):13-22
pubmed: 23588955
Cancer. 2018 Jan 1;124(1):21-35
pubmed: 29165794
Curr Opin Neurol. 2009 Dec;22(6):665-74
pubmed: 19738466
Cancer. 2002 May 15;94(10):2675-80
pubmed: 12173336
J Clin Oncol. 1987 Oct;5(10):1655-62
pubmed: 3309199
Oncotarget. 2017 Aug 16;8(42):73312-73328
pubmed: 29069871
Ann Oncol. 2017 Jul 1;28(suppl_4):iv84-iv99
pubmed: 28881917
Ann Indian Acad Neurol. 2015 Apr-Jun;18(2):206-9
pubmed: 26019420
Oncologist. 2018 Jan;23(1):52-61
pubmed: 29079637